of these nuclear receptors, PPARg, is known to play a critical part in adipocyte differentiation and fat deposition and is highly expressed in this tissue [1, 11] . The PPARg receptor exists as two protein isoforms, g1 and g2, the products of alternative splicing. The PPARg2 isoform contains an N-terminal 30 aminoacid extension and has a lower mobility on SDS-PAGE gel [12] . The PPARg receptor is bound to and activated by the natural prostaglandin derivative 15-deoxy- 12, 14 -prostaglandin J 2 [13] , as well as the synthetic insulin sensitizing thiazolidinediones such as troglitazone, pioglitazone and rosiglitazone [14±19] . A close relation between the ability of different thiazolidinediones to activate PPARg and their potency as antidiabetic agents supports the importance of PPARg in the regulation of glucose and lipid metabolism and possibly insulin action [17] .
In addition PPARg mRNA has been identified in skeletal muscle [20±22] ; the major site of impaired insulin action in Type II (non-insulin-dependent) diabetes mellitus and obesity. Furthermore, PPARg mRNA expression has been found to be increased in adipose and muscle tissue of some insulin resistant obese rodents and humans [21±24] , further suggesting this receptor is involved in regulation of metabolism and insulin action. Despite its presence in human skeletal muscle, PPARg mRNA abundance is generally 5 % or less of that in adipose tissue on the basis of total RNA. This discrepancy in mRNA abundance between tissues has led some investigators to minimise or exclude a role for muscle PPARg in the control of glucose/lipid metabolism in this tissue. Recognition that PPARg protein, not message, is responsible for its gene effects, has, however, received little attention until recently when specific immunoblotting antibodies for PPARg protein became available. Recently, immunohistochemistry was used to show that PPARg protein is present within nuclei of myocytes [25] .
In previous studies from our laboratory, PPARg gene expression (mRNA) in skeletal muscle was found to be rapidly up-regulated in response to insulin treatment in both non-diabetic control and Type II diabetic subjects [22] . In the current report, other than comparing tissue distribution of PPARs in human muscle and fat, we sought to determine PPARa, PPARb and PPARg protein expression in the tissues of subjects with and without Type II diabetes. Further, we evaluated whether metabolic variables such as glucose, insulin or triglycerides, characteristically increased in Type II diabetes, might contribute to any differences in PPAR expression between these groups.
Subjects and methods
Materials. All radioisotopes were obtained from DuPont-NEN (Boston, Mass., USA). Bovine serum albumin (BSA, fraction V) was purchased from Boehringer Mannheim (Indianapolis, Ind., USA). Reagents for electrophoresis were purchased from Bio-Rad (Richmond, Calif., USA). Polyclonal antibodies for PPARg were obtained from BioMol (Plymouth Meeting, Pa., USA), for PPARb from Santa Cruz Biotechnology (Santa Cruz, Calif., USA) and for PPARg2 from Affinity BioReagents (Golden, Colo., USA). A monoclonal antibody generated against the amino terminal region of human PPARa (residues 2±101) was a gift from Dr. D. A. Winegar at Glaxo Wellcome (Research Triangle Park, N. C., USA). Anti-rabbit and anti-mouse IgG conjugated with horseradish peroxidase were purchased from Amersham (Arlington Heights, Ill., USA). SuperSubstrate chemiluminescence substrate was from Pierce (Rockford, Ill., USA). All other reagents were purchased from Sigma (St. Louis, Mo., USA), as was a monoclonal antibody against a-sarcomeric actin.
Subjects. Adipose tissue was obtained from the abdominal region, under lidocaine anaesthesia, using a side-cutting needle [26] . Muscle biopsy specimens were obtained from the vastus lateralis of 22 non-diabetic control subjects without a family history of diabetes and 14 subjects with Type II diabetes before and after a 3-h hyperinsulinaemic (300 mU × m ±2 × min
±1
) euglycaemic (5.0±5.5 mmol/l) clamp as described in detail previously [27] . Of the subjects with diabetes, seven were treated with oral antidiabetic agents (sulphonylurea, biguanide), three with insulin and four with diet only. None of the subjects was treated with thiazolidinedione agents. Glucose tolerance was determined in all subjects after a 75-g oral glucose tolerance test [28] . Subjects with diabetes had their medication withheld on the morning of biopsy. None of the control subjects were receiving any medications known to influence glucose metabolism. The Committee on Human Investigation of the University of California, San Diego approved the experimental protocol. Informed written consent was obtained from all subjects after explanation of the protocol.
Western blotting of PPAR proteins. Tissue protein lysates were prepared as described previously [29] . Western blot analysis was done by the method of Burnette [30] as detailed previously [29] . Equal amounts of total protein were loaded. Total protein content was determined by a dye-binding method [31] . All blots contained an extract of human adipocytes as an internal standard. The results were normalized to this standard to correct for blot to blot variation. The validity of the PPARg antibody was established by several criteria. The antibody recognised a doublet of 62 000±65 000 M r in 3T3-L1 adipocytes, the intensity of this band increased considerably upon differentiation from the fibroblast phenotype (Fig. 1) . A band of similar size was found with another commercially available polyclonal antibody generated in rabbits against human PPARg (Santa Cruz Biotechnology, Santa Cruz, Calif., USA). Blocking with a peptide specific for this antibody abolished the detection of this band. The antibody did not recognize overexpressed retinoid X receptor (RXR)a, b or g (kind gift of Dr. R. Mukherjee, Ligand Pharmaceuticals, San Diego, Calif., USA), nor PPARa or b. The PPARg2 protein content was determined with a commercially available polyclonal antibody generated in rabbits against a peptide sequence described to be specific for human PPARg2 [32] . The secondary antibody for PPARg, PPARg2, and PPARb was anti-rabbit IgG conjugated with horseradish peroxidase and a similarly conjugated anti-mouse IgG was used for PPARa. Muscle biopsy specimen proteins were visualised with SuperSignal, exposed to high performance chemiluminescence film (Hyperfilm ECL, Amersham Life Science, Little Chatfont, England) and quantified with the NIH image software (Bethesda, Md., USA). To rule out possible inaccuracies due to the limited range of linearity of chemiluminescence film, all muscle to fat comparisons were also quantified with a low light imaging system (ChemiImager 4000, Alpha Innotech, San Leandro, Calif., USA). Results are presented as`arbitrary units' of the intensity of the western blot bands as detected by the indicated imaging software. These results are normalised to the value for an internal control sample included on all blots to account for blot-to-blot variation.
For the analysis of other proteins, adipocyte-specific binding protein (ALBP) detection was used with a polyclonal antibody generously provided by Dr. D. Bernlohr (University of Minnesota, USA). Sarcomeric-specific a-actin was detected with a monoclonal antibody using a horseradish peroxidase conjugated anti-mouse IgG as the secondary antibody. Muscle tissue content of muscle-specific fatty-acid binding protein (mFABP) was measured by ELISA according to a previously reported method [33] .
Northern blot analysis of tissue specific genes. To evaluate the potential adipose tissue content of muscle biopsy specimens, samples were probed for the mRNA of muscle (myogenin and mFABP) and adipose ALBP tissue specific genes. From the total RNA 10 mg was size-separated by electrophoresis through denaturing formaldehyde 1±1.5 % agarose gel and transferred to a nitrocellulose membrane (Nytran, Schleicher & Schuell, Keene, N. H., USA). To control for gel loading, the membranes were stained with methylene blue and relative intensities of the ribosomal bands were compared quantitatively using computer imaging (NIH Image). Myogenin and mFABP DNA probes for northern analysis were labelled by the hexamer priming method in the presence of a-32 P dCTP using the Ambion DECAprime II Random Priming Kit (Ambion, Austin, Tex., USA). The myogenin probe consisted of a 1.5 kb EcoR1 fragment from pBS. For the mFABP probe, a 0.5 kb EcoRI fragment of pSP6.5 containing the cDNA for mFABP was used. Specific antisense RNA probes (riboprobes) for human-ALBP were synthesised from vector pAP2, (gift of Dr. D. Bernlohr, University of Minnesota). Hybridization of DNA and RNA probes was carried out at 68°C in 10 ml of QuickHyb (Stratagene, San Diego, Calif., USA) according to the manufacturer's instructions. Relative intensities of transcript signals in the linear range were compared quantitatively using computer imaging (NIH Image). The mRNA for PPARg1,2 was measured by a quantitative reverse transcriptase-PCR assay, as described previously [22] .
Statistical analysis. Statistical significance was evaluated using Student's t test for dependent and for independent samples and regression analysis. Sample sizes were pre-calculated on the basis of the first three western blot results for PPARg in each group to achieve a statistical power of 95 % or more. Statistical power in the subgroup analysis of severely diabetic subjects compared with moderately diabetic subjects, as classified by glucose disposal rate (GDR) groups, was 80 % or more (StatSoft, STATISTICA, Tulsa, Okla., USA and GraphPad PRISM, San Diego, Calif., USA). Significance was accepted at p 0.05 or less.
Results
Subjects. Clinical characteristics (Table 1) showed fasting concentrations of blood glucose, serum insulin and HbA 1 c values all significantly higher in the subjects with Type II diabetes than in the non-diabetic subjects without a family history of diabetes. The glucose and insulin responses to an oral glucose load were also higher in the diabetes group. Insulin resistance was confirmed in the diabetes group by a significantly reduced maximum insulin-stimulated glucose disposal rate.
Baseline expression of PPARs. All three known PPAR forms are present in appreciable amounts in skeletal muscle (Fig. 2) . The PPARa protein expression was consistently greater in muscle than in adipose tissue from the same subject (five to ninefold of the value in paired fat tissue, on average 7.6-fold). Although displaying considerable intersubject variability, PPARb protein was detected at approximately the same abundance in both tissues. The PPARg protein was readily detected in muscle tissue, although the relative expression between muscle and fat (31±100 % of the value in paired fat, average = 69 %, n = 8) varied over a broad range between subjects. The relative expression of PPARg protein in fat and muscle was similar in non-diabetic and diabetic subjects. The PPARg2 protein was detectable in fat but not in muscle tissue (Fig. 1) . Thus PPARg1 seems to be the predominant isoform expressed in skeletal Results are given as arbitrary units (AU), number of subjects are given in brackets (n)
muscle. This could also explain why the PPARg band detected in muscle consistently displays a greater mobility than that in fat, which seems to contain both PPARg1 and the larger g2 isoform. (Fig. 2) . Electrophoresis conditions were selected to permit analysis of multiple proteins on the same membrane. Under other conditions a doublet for PPARg was observed in adipose tissue samples (Fig. 1) .
No difference in muscle PPARa, b or g protein expression was observed between non-diabetic and Type II diabetic subjects ( Table 2 ). The relative expression of PPARg mRNA and protein was similar in muscle tissue with significant correlations between PPARg protein and mRNA in both non-diabetic (r = 0.61, p £ 0.05) and Type II diabetic (r = 0.80, p £ 0.05) groups.
Protein expression of muscle-specific fatty acidbinding protein (mFABP), which is known to be critical for utilisation of cellular fatty acids, and of a-sarcomeric actin, a marker for the muscle phenotype [34] was also similar in both groups (Table 2) . Human adipose lipid binding protein (hALBP) mRNA and protein were detectable in adipose but not muscle tissue, consistent with minimal adipose content of muscle samples.
Regulation of baseline PPAR expression. To determine whether the in vivo metabolic environment might influence the expression of the PPARs in muscle, the relations between protein expression of these nuclear receptors and clinical characteristics were investigated. Regression analysis showed no influence of age, BMI, fasting serum lipids (non-esterified fatty acids and triglycerides), blood glucose, glycated haemoglobin and fasting serum insulin on protein expression of any PPAR in the whole study group or the diabetic and non-diabetic groups individually. Because PPARg protein has been suggested as being involved in the regulation of skeletal muscle insulin action, the relation between these two variables was explored further. The insulin-stimulated GDR, determined in each subject during the last 30 min of a hyperinsulinaemic (300 mU × m ±2 × min ±1 ), euglycaemic clamp, was used as a measure of maximum insulin action in muscle. A statistically significant inverse relation was detected between muscle PPARg protein and maximum GDR in the diabetic subjects (r = ±0.47, p £ 0.05). Conversely, in the non-diabetic subjects, there was a trend for PPARg protein to increase with increasing GDR (Fig. 3A) , the opposite of the behaviour observed in diabetic subjects, Equal amounts (10 mg) of muscle (M) and adipocyte (F) protein were separated by SDS-PAGE and western blotted by antisera against PPARa, PPARb and PPARg. For PPARa and PPARg, tissues from the same subject were run in adjacent lanes. B Relative expression of PPAR protein in skeletal muscle. Results presented as a fold of the expression in adipocytes from the same subjects. Average ± SEM for PPARa (n = 5), PPARb (n = 6), PPARg (n = 8) though this correlation did not attain statistical significance. Diabetic subjects with severe insulin resistance (GDR = 3±6 mg × kg ±1 × min, mean = 4.3, n = 6) were compared to diabetic subjects with moderate to mild resistance (GDR = 6±9, mean = 7.5, n = 8) and to non-diabetic subjects with low (GDR = 6±9, mean = 7.5, n = 7) and high (GDR = 9±16, mean = 13.3, n = 15) insulin responsiveness. This subgroup analysis showed significantly higher muscle PPARg protein in diabetic subjects with severe insulin resistance (GDR = 3±6) compared with their diabetic counterparts matched with them for age and weight with moderate to mild resistance (147 ± 23 vs 88 ± 10 AU/mg protein, p £ 0.01) and non-diabetic subjects (147 ± 23 vs 94 ± 15, p £ 0.04) with GDR = 6±9 (Fig. 3B) . Thus, the most insulin resistant diabetic subjects have the highest muscle PPARg protein expression. Except for the lean non-diabetic subjects, the subgroups were matched for BMI, eliminating obesity as a variable. Age, BMI, non-esterified fatty acids, fasting glucose, glycated haemoglobin and fasting insulin did not differ between the two diabetic subgroups with GDR = 3±6 and GDR = 6±9. The PPARa, b, mFABP and a-sarcomeric actin protein also did not differ between the four GDR subgroups (not shown).
Short-term effect on insulin on protein expression. The expression of muscle PPARg protein was not significantly changed by 3 h of insulin infusion (300 mU × m ±2 × min ±1 ) from baseline values. They remained similar in the two groups (diabetic: 144 ± 20, non-diabetic: 146 ± 14 AU/mg protein, post-clamp, see Table 2 for baseline values). The PPARg protein was also unaltered after insulin infusion, (diabetic, 107 ± 7, non-diabetic: 107 ± 13 AU/mg protein, postclamp).
Protein expression of mFABP was also not significantly different after the clamp in both subjects with diabetes (206 ± 30 vs 224 ± 11 pmol/mg protein, baseline vs clamp, respectively) and non-diabetic subjects (195 ± 17 vs 207 ± 16). The protein expression of the muscle marker, a-sarcomeric actin, was not influenced by short-term insulin exposure in either diabetic or non-diabetic subjects (not shown).
Discussion
A number of recent reports support roles for PPARa and PPARg in the regulation of glucose and lipid metabolism [2, 4±8, 14±19]. Although PPARb is detectable in a wide range of tissues [11] , including skeletal muscle and fat, it has not yet been assigned a specific role, partly due to its ubiquitous expression. For PPARa, investigators have focused their attention primarily on the liver, the tissue where PPARa was described to be predominantly expressed in rat [11] . There is, however, also information indicating that the relative expression of PPARa mRNA in human skeletal muscle is much higher than in rodent skeletal muscle [3] . Although the focus of research is widening to other cell types such as adipocytes, where PPARa is up-regulated in hyperleptinaemia-induced adipocyte dedifferentiation [35] , the role of PPARa in skeletal muscle has not yet been addressed. The high expression of PPARa protein in muscle relative to fat reported here (7.6 : 1), suggests that this nuclear protein could have an important role in muscle fatty acid metabolism.
The PPARg protein is expressed early during adipocyte differentiation [36] . Several lines of evidence suggest an involvement of PPARg in insulin action. There is a close relation between the antidiabetic, insulin-sensitising actions of the thiazolidinedione agents and their ability to bind to [18] and activate PPARg [1, 14±17, 36, 37] . Adipose tissue PPARg mRNA is positively correlated with obesity (BMI) . Weight loss leads to reductions in PPARg expression in adipocytes, together with improvement in glycaemia and lipidaemia [21] . The majority of these observations were made in adipose tissue, yet PPARg action in skeletal muscle could differ from that in the adipocyte. We [22] and others [12, 20, 21] have identified PPARg mRNA in skeletal muscle, although in lower abundance than in adipose tissue and investigated its regulation and possible involvement in insulin action.
In this study we focused our attention on protein expression because it is the protein that is responsible for the gene effects of PPARg. Given the abundance of PPARg in adipose tissue [20±22], a key concern is that the current results obtained in skeletal muscle could be influenced by the presence of adipose tissue in the biopsy samples. The following factors indicate that the contribution of adipose tissue to our results is limited. Neither mRNA, nor protein of the adipocyte specific gene ALBP was detectable in muscle biopsy specimens, indicating that the adipose content was below the detection sensitivity of these methods. If a higher adipose tissue content did contribute to differences in the PPARg protein abundance detected, then muscle biopsy samples from obese subjects could be expected to have a higher PPARg protein content. In the analysis done on the subgroups, lean non-diabetic subjects have more muscle PPARg protein than obese non-diabetic subjects who would be expected to have more fat in their muscle. Another point to note is the different mobilities of PPARg protein detected in the two tissues. The results of our PPARg2 blots suggest that the larger form seen in adipose tissue is most likely the g2 isoform. This band is not apparent in the muscle samples but it should be there if appreciable contamination by adipose tissue were present.
Although PPARg protein expression was similar in the total diabetic and non-diabetic groups, diabetic subjects with severe insulin resistance (GDR = 3±6) had a significantly higher PPARg protein compared to their more insulin sensitive counterparts matched with them for age and weight with and without diabetes (GDR = 6±9). Diabetic and non-diabetic subjects of intermediate insulin responsiveness (GDR = 6±9) were matched for BMI and have equal amounts of PPARg protein. The most insulin resistant diabetic subjects (GDR = 3±6) were matched for BMI with both intermediate groups yet have the highest PPARg protein, indicating that the key characteristic is the degree of insulin resistance and not obesity.
The increased expression of skeletal muscle PPARg protein in Type II diabetic subjects with the most severe insulin resistance could reflect either an acquired or inherited abnormality. We did not find any direct relation between metabolic variables that are characteristically increased in Type II diabetes such as glucose, insulin or lipid concentrations, and PPARg protein expression. Whether other factors unique to the metabolic environment of the diabetic state are involved in the regulation of expression or function of PPARg protein in diabetes is still to be resolved. Functionally active mutations in the PPARg gene, as possibly present in these severely insulin resistant subjects with Type II diabetes, could influence the function of the protein and lead to the abundance of PPARg as observed in these patients. It should be remembered that the final action of PPARg is dependent on a number of factors. These include, but are not limited to, the expression and function of PPARg, the abundance of the relevant endogenous ligands/activators, numerous co-activators or co-repressors and the expression and function of RXRs, the companion nuclear receptors essential for formation of the active heterodimeric complex [1] .
We have previously shown that insulin infusion rapidly increases PPARg mRNA expression in muscle [22] . That protein expression of any PPAR was not up-regulated after 3 h of insulin exposure could be due to translational kinetics which do not permit complete synthesis and processing of detectable additional quantities of the proteins in that time. In agreement with our previous finding in muscle, a recent report also found PPARg mRNA in adipose tissue to be increased after a 3-h hyperinsulinaemic, euglycaemic clamp [38] . Other investigators found no change in skeletal muscle PPARg1 mRNA after 5 h of hyperinsulinaemia [39] . This discrepancy could also represent a potential transient nature of the insulin effect to increase gene expression, it could have returned to baseline by 5 h. There are other examples of such transient responses in gene expression to insulin exposure [40] .
Several conclusions can be drawn from the current work. First, the PPAR proteins are all expressed in skeletal muscle and adipose tissue but with distinct patterns. Since in vivo activation of PPARg seems to influence both glucose and lipid concentrations whereas PPARa agonists influence triglyceride metabolism [41] , these receptors could be regulating different but complementary events in skeletal muscle. As ligands that activate PPARb have no effect on glucose or lipid concentrations [41] , the role for PPARb in skeletal muscle is still uncertain. Of these three nuclear receptors, only skeletal muscle PPARg shows differences between groups, with high protein expression in the most severely insulin resistant subjects. Furthermore, the relation between PPARg protein expression in skeletal muscle and peripheral insulin action/glucose disposal, either as a cause or a consequence, is altered in Type II diabetic compared with non-diabetic subjects. This suggests diabetes-related differences in the function or regulation of the PPARg system in skeletal muscle. No such relation appears to exist for PPARa protein. Thus, PPARg content in skeletal muscle could be an important factor through which insulin controls glucose and lipid metabolism.
